Literature DB >> 10777708

Drug-induced desensitization of insulinotropic actions of sulfonylureas.

A J Ball1, J T McCluskey, P R Flatt, N H McClenaghan.   

Abstract

K(ATP)-channel-dependent and K(ATP)-channel-independent insulin-releasing actions of the sulfonylurea, tolbutamide, were examined in the clonal BRIN-BD11 cell line. Tolbutamide stimulated insulin release at both nonstimulatory (1.1 mM) and stimulatory (16. 7 mM) glucose. Under depolarizing conditions (16.7 mM glucose plus 30 mM KCl) tolbutamide evoked a stepwise K(ATP) channel-independent insulinotropic response. Culture (18 h) with tolbutamide or the guanidine derivative BTS 67 582 (100 microM) markedly reduced (P < 0. 001) subsequent responsiveness to acute challenge with tolbutamide, glibenclamide, and BTS 67 582 but not the imidazoline drug, efaroxan. Conversely, 18 h culture with efaroxan reduced (P < 0.001) subsequent insulinotropic effects of efaroxan but not that of tolbutamide, glibenclamide, or BTS 67 582. Culture (18 h) with tolbutamide reduced the K(ATP) channel-independent actions of both tolbutamide and glibenclamide. Whereas culture with efaroxan exerted no effect on the K(ATP) channel-independent actions of sulfonylureas, BTS 67 582 abolished the response of tolbutamide and inhibited that of glibenclamide. These data demonstrate that prolonged exposure to tolbutamide desensitizes both K(ATP)-channel-dependent and -independent insulin-secretory actions of sulfonylureas, indicating synergistic pathways mediated by common sulfonylurea binding site(s). Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777708     DOI: 10.1006/bbrc.2000.2609

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Chronic stimulation induces adaptive potassium channel activity that restores calcium oscillations in pancreatic islets in vitro.

Authors:  Nathan C Law; Isabella Marinelli; Richard Bertram; Kathryn L Corbin; Cara Schildmeyer; Craig S Nunemaker
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-02-18       Impact factor: 4.310

Review 2.  Noninsulin glucose-lowering agents for the treatment of patients on dialysis.

Authors:  Colleen Flynn; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2013-01-29       Impact factor: 28.314

3.  Acute and long-term effects of nateglinide on insulin secretory pathways.

Authors:  Andrew J Ball; Peter R Flatt; Neville H McClenaghan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

Review 4.  A review of nateglinide in the management of patients with type 2 diabetes.

Authors:  Nicholas Tentolouris; Christina Voulgari; Nicholas Katsilambros
Journal:  Vasc Health Risk Manag       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.